Kalina Sanders, MD
Neurology · Jacksonville, FLNPI 1487704953
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $427,405 of the $544,170 with a category attached, or 78.5%. It is spread thinly across 58 manufacturers, the largest accounting for just 23.9%. Reporting peaked in 2019 at $130,495 and has fallen 59.3% since, to $53,110 in 2025. Among neurology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,354 payments — averaging $401.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$130K
- Genentech USA, Inc.$127K
- EMD Serono, Inc.$74K
- TG Therapeutics, Inc.$61K
- Sanofi$46K
- Johnson & Johnson$38K
- plus $68K from 52 others
Across 95 payments — averaging $3619.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$268K
- Novartis$62K
- Sanofi$14K
What the payments were for
- Consulting fees$57,59011%
- Speaking & faculty fees$427,40579%
- Grants$1500%
- Travel & lodging$28,6505%
- Food & beverage$29,5245%
- Education$8510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$544,170 in reported general payments places this provider in the 95th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CopaxoneGlatiramer Acetate | 77 | $556,850 |
| Kesimpta PenOfatumumab | 27 | $364,474 |
| AubagioTeriflunomide | 26 | $292,147 |
| TecfideraDimethyl Fumarate | 21 | $188,335 |
| RebifInterferon Beta-1a/Albumin | 15 | $183,150 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 18 | $180,188 |
| ZeposiaOzanimod Hydrochloride | 17 | $156,204 |
| GilenyaFingolimod Hcl | 12 | $120,401 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 13 | $105,732 |
| Aimovig AutoinjectorErenumab-Aooe | 68 | $55,363 |
| FingolimodFingolimod Hcl | 41 | $51,078 |
| BotoxOnabotulinumtoxina | 35 | $51,016 |
| Glatiramer Acetate | 27 | $38,149 |
| Teriflunomide | 99 | $31,604 |
| QuliptaAtogepant | 25 | $30,251 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Copaxone | $891 | $556,85077 claims |
| SanofiAubagio | $45,519 | $292,14726 claims |
| BiogenTecfidera | $129,958 | $188,33521 claims |
| EMD Serono, Inc.Rebif | $74,367 | $183,15015 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $123 | $180,18818 claims |
| E.r. Squibb & Sons, L.L.C.Zeposia | $26,267 | $156,20417 claims |
| NovartisGilenya | $1,970 | $120,40112 claims |
| AbbVieBotox, Qulipta, Ubrelvy | $1,484 | $101,46276 claims |
| PfizerNurtec Odt | $227 | $23,92317 claims |
| SandozGlatopa | $75 | $23,71415 claims |
| UCB, Inc.Neupro | $391 | $10,17412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,434 neurology providers in Florida.
Other neurology in Jacksonville
- Steven ToenjesJacksonville$695K
- Zhigao HuangJacksonville$613K
- Syed AsadJacksonville$302K
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
- Matthew BakerNaples$1.4M
- Donald NegroskiSarasota$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.